MoonLake Immunotherapeutics (MLTX) Misses Q2 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to MoonLake Immunotherapeutics (MLTX) Misses Q2 EPS by 15c

Guggenheim on 'Best Idea' Moonlake Immunotherapeutics (MLTX): 'We Continue To Anticipate Highly Positive Pivotal HS Readout Around Sept (2H)'

August 5, 2025 12:26 PM EDT

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $80.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX).

The analyst comments "Key Message: Our key takeaways from MLTX's 2Q25 release are: (1) Highly-anticipated Phase III VELA results that evaluate sonelokimab (SLK; small nanobody with dual IL-17A/F targeting) in hidradenitis suppurativa (HS) remain on-track for "around" September. Last patient, last visit has occurred in VELA-2; VELA-1 is on-track to complete in August. Assuming ~4-6 weeks of data analysis, we think data are likely... More